Top

Journal of Translational Medicine

Published in:

Open Access 01-12-2022 | Research

Single-cell transcriptomic analysis reveals a novel cell state and switching genes during hepatic stellate cell activation in vitro

Authors: Hua Wang, Shaoping Zheng, Hongbo Jiang, Xuejia Wang, Fengqin Zhou, Zhihong Weng

Published in: Journal of Translational Medicine | Issue 1/2022

Abstract

Background

The transformation of hepatic stellate cell (HSC) to myofibroblast is a key event during liver fibrogenesis. However, the differentiation trajectory of HSC-to-myofibroblast transition and the switching genes during this process remains not well understood.

Methods

We applied single-cell sequencing data to reconstruct a single-lineage pseudotime trajectory of HSC transdifferentiation in vitro and analyzed the gene expression patterns along the trajectory. GeneSwitches was used to identify the order of critical gene expression and functional events during HSC activation.

Results

A novel cell state during HSC activation was revealed and the HSCs belonging to this state may be an important origin of cancer-associated fibroblasts (CAFs). Combining single-cell transcriptomics with GeneSwitches analyses, we identified some distinct switching genes and the order at which these switches take place for the new state of HSC and the classic culture-activated HSC, respectively. Based on the top switching genes, we established a four-gene combination which exhibited highly diagnostic accuracy in predicting advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) or hepatitis B (HBV).

Conclusion

Our study revealed a novel cell state during HSC activation which may be relevant to CAFs, and identified switching genes that may play key roles in HSC transdifferentiation and serve as predictive markers of advanced fibrosis in patients with chronic liver diseases.

Available only for authorised users

Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37–55.CrossRefPubMed

Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64:830–41.CrossRefPubMed

Wang P, Koyama Y, Liu X, Xu J, Ma HY, Liang S, et al. Promising therapy candidates for liver fibrosis. Front Physiol. 2016;7:47.PubMedPubMedCentral

Dobie R, Wilson-Kanamori JR, Henderson BEP, Smith JR, Matchett KP, Portman JR, et al. Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis. Cell Rep. 2019;29(7):1832-1847.e8.CrossRefPubMedPubMedCentral

Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R, Tacke F. Single cell RNA sequencing identifies subsets of hepatic stellate cells and myofibroblasts in liver fibrosis. Cells. 2019;8(5):503. https://doi.org/10.3390/cells8050503.CrossRefPubMedCentral

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–20. https://doi.org/10.1038/nbt.4096.CrossRefPubMedPubMedCentral

Lall S, Sinha D, Bandyopadhyay S, Sengupta D. Structure—aware principal component analysis for single-cell RNA-seq data. J Comput Biol. 2018. https://doi.org/10.1089/cmb.2018.0027.CrossRefPubMed

Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495–502. https://doi.org/10.1038/nbt.3192.CrossRefPubMedPubMedCentral

Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14(10):979–82. https://doi.org/10.1038/nmeth.4402.CrossRefPubMedPubMedCentral

10.

Cao EY, Ouyang JF, Rackham OJL. GeneSwitches: ordering gene expression and functional events in single-cell experiments. Bioinformatics. 2020;36(10):3273–5. https://doi.org/10.1093/bioinformatics/btaa099.CrossRefPubMed

11.

McFadden D. Conditional logit analysis of qualitative choice behavior. Front Econometr. 1974;104–142.

12.

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–25. https://doi.org/10.1016/j.cels.2015.12.004.CrossRefPubMedPubMedCentral

13.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

14.

Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology. 2014;59(2):471–82.CrossRefPubMed

15.

Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015;61(5):1565–78.CrossRefPubMed

16.

Wang M, Gong Q, Zhang J, Chen L, Zhang Z, Lu L, et al. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Sci Rep. 2017;7:43446. https://doi.org/10.1038/srep43446.CrossRefPubMedPubMedCentral

17.

Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39(6):866-882.e11. https://doi.org/10.1016/j.ccell.2021.03.012.CrossRefPubMed

18.

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https://doi.org/10.1186/1471-2105-12-77.CrossRefPubMedPubMedCentral

19.

Wickham H. ggplot2: elegant graphics for data analysis. Berlin: Springer; 2009.CrossRef

20.

Terkelsen MK, Bendixen SM, Hansen D, Scott EAH, Moeller AF, Nielsen R, et al. Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury. Hepatology. 2020;72(6):2119–33. https://doi.org/10.1002/hep.31215.CrossRefPubMed

21.

Liu X, Liu D, Qian D, Dai J, An Y, Jiang S, et al. Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 degradation in hepatocellular carcinoma cells. J Biol Chem. 2012;287(23):19599–609. https://doi.org/10.1074/jbc.M112.363622.CrossRefPubMedPubMedCentral

22.

Cao J, Zhao M, Liu J, Zhang X, Pei Y, Wang J, et al. RACK1 promotes self-renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing nanog. Theranostics. 2019;9(3):811–28. https://doi.org/10.7150/thno.29271.CrossRefPubMedPubMedCentral

23.

Li Y, Lu C, Xing G, Zhu Y, He F. Macrophage migration inhibitory factor directly interacts with hepatopoietin and regulates the proliferation of hepatoma cell. Exp Cell Res. 2004;300(2):379–87. https://doi.org/10.1016/j.yexcr.2004.07.019.CrossRefPubMed

24.

Zhou X, Wang X, Huang K, Liao X, Yang C, Yu T, et al. Investigation of the clinical significance and prospective molecular mechanisms of cystatin genes in patients with hepatitis B virus-related hepatocellular carcinoma. Oncol Rep. 2019;42(1):189–201. https://doi.org/10.3892/or.2019.7154.CrossRefPubMedPubMedCentral

25.

Zhang C, Wu S, Yang XD, Xu H, Ma T, Zhu QX. Identification of key genes for hepatitis delta virus-related hepatocellular carcinoma by bioinformatics analysis. Turk J Gastroenterol. 2021;32(2):169–77. https://doi.org/10.5152/tjg.2020.191003.CrossRefPubMedPubMedCentral

26.

Yin Z, Dong C, Jiang K, Xu Z, Li R, Guo K, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol. 2019;12(1):101. https://doi.org/10.1186/s13045-019-0782-x.CrossRefPubMedPubMedCentral

27.

Berkel C, Cacan E. DYNLL1 is hypomethylated and upregulated in a tumor stage- and grade-dependent manner and associated with increased mortality in hepatocellular carcinoma. Exp Mol Pathol. 2020;117: 104567. https://doi.org/10.1016/j.yexmp.2020.104567.CrossRefPubMed

28.

Yao L, Zhou Y, Sui Z, Zhang Y, Liu Y, Xie H, et al. HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells. EBioMedicine. 2019;48:117–29. https://doi.org/10.1016/j.ebiom.2019.09.012.CrossRefPubMedPubMedCentral

29.

Yao B, Li Y, Chen T, Niu Y, Wang Y, Yang Y, et al. Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway. Clin Transl Med. 2021;11(3): e366. https://doi.org/10.1002/ctm2.366.CrossRefPubMedPubMedCentral

30.

Li L, Li X, Zhang Q, Ye T, Zou S, Yan J. EIF5A expression and its role as a potential diagnostic biomarker in hepatocellular carcinoma. J Cancer. 2021;12(16):4774–9. https://doi.org/10.7150/jca.58168.CrossRefPubMedPubMedCentral

31.

Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, et al. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res. 2013;19(7):1827–37. https://doi.org/10.1158/1078-0432.CCR-12-1641.CrossRefPubMed

32.

El Taghdouini A, Sørensen AL, Reiner AH, Coll M, Verhulst S, Mannaerts I, et al. Genome-wide analysis of DNA methylation and gene expression patterns in purified, uncultured human liver cells and activated hepatic stellate cells. Oncotarget. 2015;6(29):26729–45. https://doi.org/10.18632/oncotarget.4925.CrossRefPubMedPubMedCentral

33.

Chen W, Wu X, Yan X, Xu A, Yang A, You H. Multitranscriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression independent of etiology. Am J Physiol Gastrointest Liver Physiol. 2019;316(6):G744–54. https://doi.org/10.1152/ajpgi.00339.2018.CrossRefPubMed

34.

Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411.CrossRefPubMed

35.

Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol. 2012;6(1):67–80.CrossRefPubMed

36.

Bourd-Boittin K, LePabic H, Bonnier D, L’Helgoualc’h A, Théret N. RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis. J Biol Chem. 2008;283(38):26000–9. https://doi.org/10.1074/jbc.M709829200.CrossRefPubMedPubMedCentral

37.

Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, et al. Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. Cell Death Dis. 2016;7(12): e2560. https://doi.org/10.1038/cddis.2016.430.CrossRefPubMedPubMedCentral

38.

O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol. 2018;24(39):4436–47. https://doi.org/10.3748/wjg.v24.i39.4436.CrossRefPubMedPubMedCentral

39.

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(26):1650–9. https://doi.org/10.1056/NEJM198612253152606.CrossRefPubMed

40.

Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 2009;100(4):646–53. https://doi.org/10.1111/j.1349-7006.2009.01087.x.CrossRefPubMed

41.

Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, Zhou J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009;131(4):498–510. https://doi.org/10.1309/AJCP86PPBNGOHNNL.CrossRefPubMed

42.

Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019;20(7):1723. https://doi.org/10.3390/ijms20071723.CrossRefPubMedCentral

43.

Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153–86. https://doi.org/10.1146/annurev-pathol-052016-100322.CrossRefPubMed

44.

Tahmasebi Birgani M, Carloni V. Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy. Int J Mol Sci. 2017;18(2):405. https://doi.org/10.3390/ijms18020405.CrossRefPubMedCentral

45.

Xie ZY, Wang FF, Xiao ZH, Liu SF, Lai YL, Tang SL. Long noncoding RNA XIST enhances ethanol-induced hepatic stellate cells autophagy and activation via miR-29b/HMGB1 axis. IUBMB Life. 2019;71(12):1962–72. https://doi.org/10.1002/iub.2140.CrossRefPubMed

46.

Ryter SW. Heme oxygenase-1/carbon monoxide as modulators of autophagy and inflammation. Arch Biochem Biophys. 2019;678: 108186. https://doi.org/10.1016/j.abb.2019.108186.CrossRefPubMed

47.

Sun P, Zhang S, Qin X, Chang X, Cui X, Li H, et al. Foot-and-mouth disease virus capsid protein VP2 activates the cellular EIF2S1-ATF4 pathway and induces autophagy via HSPB1. Autophagy. 2018;14(2):336–46. https://doi.org/10.1080/15548627.2017.1405187.CrossRefPubMedPubMedCentral

48.

Winer H, Fraiberg M, Abada A, Dadosh T, Tamim-Yecheskel BC, Elazar Z. Autophagy differentially regulates TNF receptor Fn14 by distinct mammalian Atg8 proteins. Nat Commun. 2018;9(1):3744. https://doi.org/10.1038/s41467-018-06275-1.CrossRefPubMedPubMedCentral

49.

Kreis NN, Louwen F, Yuan J. The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers (Basel). 2019;11(9):1220. https://doi.org/10.3390/cancers11091220.CrossRef

50.

Kalas W, Swiderek E, Switalska M, Wietrzyk J, Rak J, Strzadala L. Thrombospondin-1 receptor mediates autophagy of RAS-expressing cancer cells and triggers tumour growth inhibition. Anticancer Res. 2013;33(4):1429–38.PubMed

51.

Okazaki H, Hirakawa S, Shudou M, Nakaoka Y, Shirakata Y, Miyata K, et al. Targeted overexpression of Angptl6/angiopoietin-related growth factor in the skin promotes angiogenesis and lymphatic vessel enlargement in response to ultraviolet B. J Dermatol. 2012;39(4):366–74. https://doi.org/10.1111/j.1346-8138.2011.01396.x.CrossRefPubMed

52.

Gerhard GS, Hanson A, Wilhelmsen D, Piras IS, Still CD, Chu X, et al. AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p. PLoS ONE. 2019;14(7): e0219764. https://doi.org/10.1371/journal.pone.0219764.CrossRefPubMedPubMedCentral

53.

Ikenaga N, Peng ZW, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017;66(9):1697–708. https://doi.org/10.1136/gutjnl-2016-312473.CrossRefPubMed

54.

Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617–24. https://doi.org/10.1038/nm.3282.CrossRefPubMed

55.

Liu Z, Xu Y, Zhang W, Gao X, Luo G, Song H, et al. Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics. Sci Rep. 2021;11(1):10381. https://doi.org/10.1038/s41598-021-90001-3.CrossRefPubMedPubMedCentral

56.

Binder JX, Pletscher-Frankild S, Tsafou K, Stolte C, O’Donoghue SI, Schneider R, et al. COMPARTMENTS: unification and visualization of protein subcellular localization evidence. Database (Oxford). 2014;2014:012. https://doi.org/10.1093/database/bau012. CrossRef

Title: Single-cell transcriptomic analysis reveals a novel cell state and switching genes during hepatic stellate cell activation in vitro
Authors: Hua Wang
Shaoping Zheng
Hongbo Jiang
Xuejia Wang
Fengqin Zhou
Zhihong Weng
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-022-03263-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Comparison of dynamic susceptibility contrast enhanced MR and FDG-PET brain studies in patients with Alzheimer’s disease and amnestic mild cognitive impairment

Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis

5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Correction to: miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3

Building a model for predicting metabolic syndrome using artificial intelligence based on an investigation of whole-genome sequencing

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage